Constellation heading for pivotal myelofibrosis trial as ASH data lifts shares

Constellation's shares nearly doubled in value Tuesday after the company reported Phase II data showing CPI-0610 plus SOC Jakavi could improve response rates for myelofibrosis patients, along with plans to launch Phase III testing of the therapy next year.

The data from the Phase II MANIFEST study were released in abstracts ahead of the American Society of Hematology (ASH) meeting in December. Constellation Pharmaceuticals Inc. (NASDAQ:CNST) gained $13.33 (90%) to $28.10 on the day. ...